久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

CPhI Monthly Podcast: The opportunities and challenges of providing fill and finish services for mRNA platforms

cphi-onlineAugust 23, 2021

Tag: CPhI , mRNA , SARS-CoV-2

mRNA (Messenger ribonucleuc acid) technology has been thrust into the limelight in recent months, with the platform proving to be the springboard for two approved vaccines against the SARS-CoV-2 virus.

CPhI Monthly Podcast: The opportunities and challenges of providing fill and finish services for mRNA platforms

The complex science around mRNA is very different from that of small molecule traditional pharmaceuticals or traditional biologics such as monoclonal antibodies.

This month we speak to Christy Eatmon, Global SME, Sterile Drug Products, Pharma Services Group at Thermo Fisher Scientific about how CDMOs are providing their manufacturing and fill finish expertise to bring mRNA vaccines to market in as timely a fashion as possible.


Previous:Curia lays out plans to expand complex API manufacturing capacity

Next:US clears BMS' Opdivo as first adjuvant therapy for bladder cancer

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service